Comparison of Angioplasty/Drug Coated Balloon/Laser + Drug Coated Balloon for Femoropopliteal Artery In-stent Restenosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

222 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2020-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this multicenter triple-arm randomized study is to compare two innovative techniques with the gold standard currently used and providing unsatisfactory results for the In-Stent Restenosis (ISR) treatment in femoro-popliteal arteries. This protocol compares the use of drug-coated balloons (paclitaxel - antimitotic) used alone or in association with the Excimer Laser to recalibrate the vessel lumen into the stent by destroying the whole fibrous material to the standard angioplasty using plain balloons. INTACT study main objective is to assess cost-effectiveness ratio of the treatment of femoropopliteal artery in-stent restenosis by comparing these two innovative strategies and the standard one in terms of cost per Qaly (Quality adjusted life-years) gained at 18 months from a collective perspective.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis

NCT01330628

Peripheral Arterial Disease

COMPLETED PHASE2/PHASE3

Clinical Study of Excimer Laser and Drug Coated Balloon Versus Excimer Laser and Plain Balloon Versus Plain Balloon and Drug Coated Balloon to Treat Femoropopliteal In-stent Restenosis

NCT04365062

Atherosclerosis of Artery In-stent Arterial Restenosis

UNKNOWN NA

TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions

NCT03306199

Peripheral Arterial Disease

COMPLETED

Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents

NCT02528474

Coronary Artery Disease

TERMINATED NA

Drug Coated Balloons for Prevention of Restenosis

NCT00696956

Atherosclerosis Restenosis Limb Ishemia

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The publication show that there is probably an effectiveness gradient (expressed as a proportion of patients with in-stent restenosis a 18 months after the intervention of the first stenosis reduction): standard balloons would be less effective than active balloons themselves less effective than in combination with the excimer laser. Reducing the risk of In-Stent Restenosis has major implications for the treatment of patients because it reduces the use of arterial bypass or amputation, if unable to perform revascularization.

Based on these promising results of efficiency, we can hypothesize that the active balloons in combination with the Excimer laser would improve the quality of life of patients while reducing the cost of their treatment, this compared to only assets balloons. This same improvement in quality of life with reduced costs of care would be observed for only assets compared to standard balloons. In health economic terms, it is therefore likely that the strategy combining assets balloons and Excimer laser is dominant over assets balloons themselves dominant over standard balloons.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angioplasty, Balloon

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard balloon

Angioplasty with use of standard balloons

Group Type NO_INTERVENTION

No interventions assigned to this group

Drug-coated balloons

Angioplasty with use of drug-coated balloons

Group Type EXPERIMENTAL

Drug-coated balloons

Intervention Type DEVICE

Drug-coated balloons and laser

Angioplasty with use of drug-coated balloons in association with Excimer Laser

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

In.Pact (Medtronic) SPECTRANETICS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient of age \> 18 years
* Patient with previously peripheral implanted stent(s) located in or extending to the popliteal artery
* Patient who received this stent between 3-36 months before inclusion
* Patient with one or more in-stent restenosis lesion(s) \> 70% in the same arterial segment in association with clinical symptoms of claudication or an critical limb ischemia with Rutherford classification of 2, 3, 4 or 5
* Reference vessel diameter between 4 and 7 mm
* Patient affiliated to a social security regimen
* EC-approved consent form signed by the participant and the investigator (must be signed prior initiation of any study related intervention)

Exclusion Criteria

* Life expectancy \>18 months
* Patient already included in this study (recruitment of the contralateral leg is not allowed)
* Patient contraindicated for the use of antiplatelet therapy
* Pregnant or breast-feeding women
* Patient with a target limb infection being treated
* Patient with a procoagulant blood disease
* Patient with history of contrast agents allergies
* Patient with intolerance to paclitaxel
* Patient with severe renal impairment (GFR \<30 ml / min / 1.73 m²) or patient with a creatinine clearance \<15 ml / min
* External compression of previously implanted stent
* Patient participating in any clinical trial using another investigational drug or product which could interfere with the interpretation of the trial results.
* Patient under trusteeship or guardianship

* Inflow (above) severe lesion \>70% or occlusion untreated satisfactorily (residual lesion\> 50%) before the management of the target lesion
* Perforation, dissection or lesions on the arterial network access requiring an assumption prior to randomization
* Stent fracture grade 4 or 5 at the target lesion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No